Journal Home > Volume 2 , Issue 1
Brain Science Advances 2016, 2(1): 50-58 https://doi.org/10.18679/CN11-6030_R.2016.007
Review Article | Open Access | Issue | Published: 01 March 2016

Cell-based therapy in Alzheimer’s disease: Current knowledge and perspective

Show Author's Information Liyan Qiao1( ),  Hongyun Huang2,3,  Lin Chen4
Department of Neurology, Tsinghua University Yuquan Hospital, Beijing 100040, China
Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing 100039, China
Beijing Hongtianji Neuroscience Academy, Lingxiu Building, Beijing 100043, China
Department of Neurosurgery, Tsinghua University Yuquan Hospital, Beijing 100040, China
Keywords:
Alzheimer’s disease, cell therapy, stem cells, neurogenesis
Cite this article:
Qiao L, Huang H, Chen L. Cell-based therapy in Alzheimer’s disease: Current knowledge and perspective. Brain Science Advances, 2016, 2(1): 50-58. https://doi.org/10.18679/CN11-6030_R.2016.007
Download citation
EndNote(RIS)
BibTeX

377

Views

5

Downloads

Citations

0

Crossref

N/A

WoS

N/A

Scopus

N/A

CSCD

Abstract Full text About this article

Alzheimer’s disease (AD) is the most prevalent type of dementia, and its neuropathology is characterized by the deposition of insoluble β-amyloid (Aβ) peptides, intracellular neurofibrillary tangles, amyloid angiopathy, age-related brain atrophy, synaptic pathology, white matter rarefaction, granulovacuolar degeneration, neuron loss, and neuroinflammation. Although much is known about the neurobiology of AD, very few conventional therapies are available to arrest or slow the disease. There is an urgent need for novel therapeutic approaches for AD. AD subjects have significantly fewer viable precursor cells in the hippocampus compared with age-matched healthy control subjects. However, the viable precursor cells that remain in AD and age-matched healthy control brain specimens can be induced to differentiate. To facilitate or mimic the natural compensatory effect in AD, cell therapy, including endogenous and exogenous stem cells, has been considered in AD. In this review, we focus on the history and development of cell therapy in AD, and consider the role of cell therapy as a potential treatment for AD.


menu
Abstract
Full text
Outline
About this article

Cell-based therapy in Alzheimer’s disease: Current knowledge and perspective

Show Author's information Liyan Qiao1( ), Hongyun Huang2,3, Lin Chen4
Department of Neurology, Tsinghua University Yuquan Hospital, Beijing 100040, China
Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing 100039, China
Beijing Hongtianji Neuroscience Academy, Lingxiu Building, Beijing 100043, China
Department of Neurosurgery, Tsinghua University Yuquan Hospital, Beijing 100040, China

Abstract

Alzheimer’s disease (AD) is the most prevalent type of dementia, and its neuropathology is characterized by the deposition of insoluble β-amyloid (Aβ) peptides, intracellular neurofibrillary tangles, amyloid angiopathy, age-related brain atrophy, synaptic pathology, white matter rarefaction, granulovacuolar degeneration, neuron loss, and neuroinflammation. Although much is known about the neurobiology of AD, very few conventional therapies are available to arrest or slow the disease. There is an urgent need for novel therapeutic approaches for AD. AD subjects have significantly fewer viable precursor cells in the hippocampus compared with age-matched healthy control subjects. However, the viable precursor cells that remain in AD and age-matched healthy control brain specimens can be induced to differentiate. To facilitate or mimic the natural compensatory effect in AD, cell therapy, including endogenous and exogenous stem cells, has been considered in AD. In this review, we focus on the history and development of cell therapy in AD, and consider the role of cell therapy as a potential treatment for AD.

Keywords: Alzheimer’s disease, cell therapy, stem cells, neurogenesis

References(81)

[1]
Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 2015, 11(3): 332–384.
DOI Google Scholar
[2]
Drachman DA. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer’s disease. Alzheimers Dement 2014, 10(3): 372–380.
DOI Google Scholar
[3]
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 2012, 8(1): 1–13.
DOI Google Scholar
[4]
Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 2012, 71(5): 362–381.
DOI Google Scholar
[5]
Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res 2013, 24(3): 358–369.
DOI Google Scholar
[6]
Muoio V, Persson PB, Sendeski MM. The neurovascular unit-concept review. Acta Physiol (Oxf) 2014, 210(4): 790–798.
DOI Google Scholar
[7]
Baloyannis SJ, Baloyannis IS. The vascular factor in Alzheimer’s disease: A study in Golgi technique and electron microscopy. J Neurol Sci 2012, 322(1-2): 117–121.
DOI Google Scholar
[8]
Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 2009, 118(1): 103–113.
DOI Google Scholar
[9]
Terry AV Jr., Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003, 306(3): 821–827.
DOI Google Scholar
[10]
Altman J. Are new neurons formed in the brains of adult mammals? Science 1962, 135(3509): 1127–1128.
DOI Google Scholar
[11]
Altman J. Autoradiographic investigation of cell proliferation in the brains of rats and cats. Anat Rec 1963, 145: 573–591.
DOI Google Scholar
[12]
Altman J, Das GD. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol 1965, 124(3): 319–335.
DOI Google Scholar
[13]
Altman J. Autoradiographic and histological studies of postnatal neurogenesis. IV. Cell proliferation and migration in the anterior forebrain, with special reference to persisting neurogenesis in the olfactory bulb. J Comp Neurol 1969, 137(4): 433–457.
DOI Google Scholar
[14]
Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH. Neurogenesis in the adult human hippocampus. Nat Med 1998, 4(11): 1313–1317.
DOI Google Scholar
[15]
Lovell MA, Geiger H, Van Zant GE, Lynn BC, Markesbery WR. Isolation of neural precursor cells from Alzheimer’s disease and aged control postmortem brain. Neurobiol Aging 2006, 27(7): 909–917.
DOI Google Scholar
[16]
Kakimura J, Kitamura Y, Takata K, Umeki M, Suzuki S, Shibagaki K, Taniguchi T, Nomura Y, Gebicke-Haerter PJ, Smith MA, et al. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J 2002, 16(6): 601–603.
DOI Google Scholar
[17]
Koren J, 3rd, Jinwal UK, Lee DC, Jones JR, Shults CL, Johnson AG, Anderson LJ, Dickey CA. Chaperone signalling complexes in Alzheimer’s disease. J Cell Mol Med 2009, 13(4): 619–630.
DOI Google Scholar
[18]
Choi SS, Lee SR, Kim SU, Lee HJ. Alzheimer’s disease and stem cell therapy. Exp Neurobiol 2014, 23(1): 45–52.
DOI Google Scholar
[19]
Wilhelmus MM, de Waal RM, Verbeek MM. Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer’s disease. Mol Neurobiol 2007, 35(3): 203–216.
DOI Google Scholar
[20]
Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, Takahashi R, Murata S, Tanaka K, Takashima A. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 2005, 94(5): 1254–1263.
DOI Google Scholar
[21]
Jinwal UK, O’Leary JC, Borysov SI, Jones JR, Li Q, Koren J, Abisambra JF, Vestal GD, Lawson LY, Johnson AG, Blair LJ, Jin Y, Miyata Y, Gestwicki JE, Dickey CA. Hsc70 rapidly engages tau after microtubule destabilization. J Biol Chem 2010, 285(22): 16798–16805.
DOI Google Scholar
[22]
Ridwan S, Bauer H, Frauenknecht K, Hefti K, von Pein H, Sommer CJ. Distribution of the hematopoietic growth factor G-CSF and its receptor in the adult human brain with specific reference to Alzheimer’s disease. J Anat 2014, 224(4): 377–391.
DOI Google Scholar
[23]
Prakash A, Medhi B, Chopra K. Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-beta induced experimental model of Alzheimer’s disease. Pharmacol Biochem Behav 2013, 110: 46–57.
DOI Google Scholar
[24]
Tsai KJ, Tsai YC, Shen CK. G-CSF rescues the memory impairment of animal models of Alzheimer’s disease. J Exp Med 2007, 204(6): 1273–1280.
DOI Google Scholar
[25]
Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, Cao C, Arendash GW. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer’s mice. Neuroscience 2009, 163(1): 55–72.
DOI Google Scholar
[26]
Shin JW, Lee JK, Lee JE, Min WK, Schuchman EH, Jin HK, Bae JS. Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell-derived factor-1alpha in an Alzheimer’s disease mouse model. Stem Cells 2011, 29(7): 1075–1089.
DOI Google Scholar
[27]
Parthsarathy V, Holscher C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS One 2013, 8(3): e58784.
DOI Google Scholar
[28]
Chang KA, Kim JA, Kim S, Joo Y, Shin KY, Kim HS, Suh YH. Therapeutic potentials of neural stem cells treated with fluoxetine in Alzheimer’s disease. Neurochem Int 2012, 61(6): 885–891.
DOI Google Scholar
[29]
Chadwick W, Mitchell N, Caroll J, Zhou Y, Park SS, Wang L, Becker KG, Zhang Y, Lehrmann E, Wood WH, Martin B, Maudsley S. Amitriptyline-mediated cognitive enhancement in aged 3xTg Alzheimer’s disease mice is associated with neurogenesis and neurotrophic activity. PLoS One 2011, 6(6): e21660.
DOI Google Scholar
[30]
Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 2001, 276(27): 24985–24990.
DOI Google Scholar
[31]
Moghadam FH, Alaie H, Karbalaie K, Tanhaei S, Nasr Esfahani MH, Baharvand H. Transplantation of primed or unprimed mouse embryonic stem cell-derived neural precursor cells improves cognitive function in Alzheimerian rats. Differentiation 2009, 78(2-3): 59–68.
DOI Google Scholar
[32]
Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17(4): 331–340.
DOI Google Scholar
[33]
Oh SH, Kim HN, Park HJ, Shin JY, Lee PH. Mesenchymal stem cells increase hippocampal neurogenesis and neuronal differentiation by enhancing the wnt signaling pathway in an Alzheimer’s disease model. Cell Transplant 2015, 24(6): 1097–1109.
DOI Google Scholar
[34]
Zilka N, Zilkova M, Kazmerova Z, Sarissky M, Cigankova V, Novak M. Mesenchymal stem cells rescue the Alzheimer’s disease cell model from cell death induced by misfolded truncated tau. Neuroscience 2011, 193:330–337.
DOI Google Scholar
[35]
Khairallah MI, Kassem LA, Yassin NA, El Din MA, Zekri M, Attia M. The hematopoietic growth factor “erythropoietin” enhances the therapeutic effect of mesenchymal stem cells in Alzheimer’s disease. Pak J Biol Sci 2014, 17(1): 9–21.
DOI Google Scholar
[36]
Lee HJ, Lee JK, Lee H, Shin JW, Carter JE, Sakamoto T, Jin HK, Bae JS. The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer’s disease. Neurosci Lett 2010, 481(1): 30–35.
DOI Google Scholar
[37]
Shin JY, Park HJ, Kim HN, Oh SH, Bae JS, Ha HJ, Lee PH. Mesenchymal stem cells enhance autophagy and increase beta-amyloid clearance in Alzheimer disease models. Autophagy 2014, 10(1): 32–44.
DOI Google Scholar
[38]
Naaldijk Y, Jager C, Fabian C, Leovsky C, Bluher A, Rudolph L, Hinze A, Stolzing A. Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice. Neuropathol Appl Neurobiol 2016.
DOI Google Scholar
[39]
Lee JK, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer’s disease mouse model. Neurosci Lett 2009, 450(2): 136–141.
DOI Google Scholar
[40]
Bae JS, Jin HK, Lee JK, Richardson JC, Carter JE. Bone marrow-derived mesenchymal stem cells contribute to the reduction of amyloid-beta deposits and the improvement of synaptic transmission in a mouse model of pre-dementia Alzheimer’s disease. Curr Alzheimer Res 2013, 10(5): 524– 531.
DOI Google Scholar
[41]
Park D, Yang G, Bae DK, Lee SH, Yang YH, Kyung J, Kim D, Choi EK, Choi KC, Kim SU, Kang SK, Ra JC, Kim YB. Human adipose tissue-derived mesenchymal stem cells improve cognitive function and physical activity in ageing mice. J Neurosci Res 2013, 91(5): 660–670.
DOI Google Scholar
[42]
Kim S, Chang KA, Kim J, Park HG, Ra JC, Kim HS, Suh YH. The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer’s disease mice. PLoS One 2012, 7(9): e45757.
DOI Google Scholar
[43]
Diaz-Moreno M, Hortiguela R, Goncalves A, Garcia-Carpio I, Manich G, Garcia-Bermudez E, Moreno-Estelles M, Eguiluz C, Vilaplana J, Pelegri C, Vilar M, Mira H. Abeta increases neural stem cell activity in senescence-accelerated SAMP8 mice. Neurobiol Aging 2013, 34(11): 2623–2638.
DOI Google Scholar
[44]
Yamasaki TR, Blurton-Jones M, Morrissette DA, Kitazawa M, Oddo S, LaFerla FM. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci 2007, 27(44): 11925–11933.
DOI Google Scholar
[45]
Ryu JK, Cho T, Wang YT, McLarnon JG. Neural progenitor cells attenuate inflammatory reactivity and neuronal loss in an animal model of inflamed AD brain. J Neuroinflammation 2009, 6: 39.
DOI Google Scholar
[46]
Zhang W, Wang PJ, Sha HY, Ni J, Li MH, Gu GJ. Neural stem cell transplants improve cognitive function without altering amyloid pathology in an APP/PS1 double transgenic model of Alzheimer's disease. Mol Neurobiol 2014, 50(2): 423–437.
DOI Google Scholar
[47]
Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 2009, 106(32): 13594–13599.
DOI Google Scholar
[48]
Xuan AG, Long DH, Gu HG, Yang DD, Hong LP, Leng SL. BDNF improves the effects of neural stem cells on the rat model of Alzheimer’s disease with unilateral lesion of fimbria-fornix. Neurosci Lett 2008, 440(3): 331–335.
DOI Google Scholar
[49]
Xuan AG, Luo M, Ji WD, Long DH. Effects of engrafted neural stem cells in Alzheimer’s disease rats. Neurosci Lett 2009, 450(2): 167–171.
DOI Google Scholar
[50]
Zhang W, Wang PJ, Gu GJ, Li MH, Gao XL. Effects of neural stem cells transplanted into an animal model of Alzheimer disease on Abeta plaques. Zhonghua Yi Xue Za Zhi 2013, 93(45): 3636–3639.
Google Scholar
[51]
Kern DS, Maclean KN, Jiang H, Synder EY, Sladek JR Jr., Bjugstad KB. Neural stem cells reduce hippocampal tau and reelin accumulation in aged Ts65Dn Down syndrome mice. Cell Transplant 2011, 20(3): 371–379.
DOI Google Scholar
[52]
Wu S, Sasaki A, Yoshimoto R, Kawahara Y, Manabe T, Kataoka K, Asashima M, Yuge L. Neural stem cells improve learning and memory in rats with Alzheimer’s disease. Pathobiology 2008, 75(3): 186–194.
DOI Google Scholar
[53]
Lee JK, Jin HK, Endo S, Schuchman EH, Carter JE, Bae JS. Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer’s disease mice by modulation of immune responses. Stem Cells 2010, 28(2): 329–343.
DOI Google Scholar
[54]
Yang H, Xie Z, Wei L, Yang S, Zhu Z, Wang P, Zhao C, Bi J. Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an AbetaPP/PS1 transgenic mouse model. Stem Cell Res Ther 2013, 4(4):76.
DOI Google Scholar
[55]
Lee HJ, Lim IJ, Park SW, Kim YB, Ko Y, Kim SU. Human neural stem cells genetically modified to express human nerve growth factor (NGF) gene restore cognition in the mouse with ibotenic acid-induced cognitive dysfunction. Cell Transplant 2012, 21(11): 2487–2496.
DOI Google Scholar
[56]
Ende N, Chen R, Ende-Harris D. Human umbilical cord blood cells ameliorate Alzheimer’s disease in transgenic mice. J Med 2001, 32(3-4): 241–247.
Google Scholar
[57]
Darlington D, Deng J, Giunta B, Hou H, Sanberg CD, Kuzmin-Nichols N, Zhou HD, Mori T, Ehrhart J, Sanberg PR, Tan J. Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-beta-associated neuropathology in Alzheimer mice. Stem Cells Dev 2013, 22(3): 412–421.
DOI Google Scholar
[58]
Nikolic WV, Hou H, Town T, Zhu Y, Giunta B, Sanberg CD, Zeng J, Luo D, Ehrhart J, Mori T, Sanberg PR, Tan J. Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev 2008, 17(3): 423–439.
DOI Google Scholar
[59]
Kim KS, Kim HS, Park JM, Kim HW, Park MK, Lee HS, Lim DS, Lee TH, Chopp M, Moon J. Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer’s disease model. Neurobiol Aging 2013, 34(10): 2408–2420.
DOI Google Scholar
[60]
Fujiwara N, Shimizu J, Takai K, Arimitsu N, Saito A, Kono T, Umehara T, Ueda Y, Wakisaka S, Suzuki T, Suzuki N. Restoration of spatial memory dysfunction of human APP transgenic mice by transplantation of neuronal precursors derived from human iPS cells. Neurosci Lett 2013, 557 Pt B: 129–134.
DOI Google Scholar
[61]
Ooi L, Sidhu K, Poljak A, Sutherland G, O'Connor MD, Sachdev P, Munch G. Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer’s disease. J Neural Transm 2013, 120(1): 103–111.
DOI Google Scholar
[62]
Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N. Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum Mol Genet 2011, 20(23): 4530–4539.
DOI Google Scholar
[63]
Demars M, Hu YS, Gadadhar A, Lazarov O. Impaired neurogenesis is an early event in the etiology of familial Alzheimer’s disease in transgenic mice. J Neurosci Res 2010, 88(10): 2103–2117.
DOI Google Scholar
[64]
Rodriguez JJ, Jones VC, Verkhratsky A. Impaired cell proliferation in the subventricular zone in an Alzheimer’s disease model. Neuroreport 2009, 20(10): 907–912.
DOI Google Scholar
[65]
Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer’s disease. J Neurochem 2002, 83(6): 1509–1524.
DOI Google Scholar
[66]
Hayashi Y, Kashiwagi K, Ohta J, Nakajima M, Kawashima T, Yoshikawa K. Alzheimer amyloid protein precursor enhances proliferation of neural stem cells from fetal rat brain. Biochem Biophys Res Commun 1994, 205(1): 936–943.
DOI Google Scholar
[67]
Chevallier NL, Soriano S, Kang DE, Masliah E, Hu G, Koo EH. Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am J Pathol 2005, 167(1): 151–159.
DOI Google Scholar
[68]
Wen PH, Shao X, Shao ZP, Hof PR, Wisniewski T, Kelley K, Friedrich Jr. VL, Ho L, Pasinetti GM, Shioi JC, Robakisa NK, Eldera GA. Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis 2002, 10(1): 8–19.
DOI Google Scholar
[69]
Zhang X, Jin G, Tian M, Qin J, Huang Z. The denervated hippocampus provides proper microenvironment for the survival and differentiation of neural progenitors. Neurosci Lett 2007, 414(2): 115–120.
DOI Google Scholar
[70]
Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 1996, 16(6): 2027–2033.
DOI Google Scholar
[71]
Zhang Q, Wu HH, Wang Y, Gu GJ, Zhang W, Xia R. Neural stem cell transplantation decreases neuroinflammation in a transgenic mouse model of Alzheimer’s disease. J Neurochem 2015.
DOI Google Scholar
[72]
Ager RR, Davis JL, Agazaryan A, Benavente F, Poon WW, LaFerla FM, Blurton-Jones M. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer’s disease and neuronal loss. Hippocampus 2015, 25(7): 813–826.
DOI Google Scholar
[73]
Lee JK, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells attenuate amyloid beta-induced memory impairment and apoptosis by inhibiting neuronal cell death. Curr Alzheimer Res 2010, 7(6): 540–548.
DOI Google Scholar
[74]
Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, Keren R, Wherrett J, Naglie G, Hamani C, Smith GS, Lozano AM. A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann Neurol 2010, 68(4): 521–534.
DOI Google Scholar
[75]
Calissano P, Matrone C, Amadoro G. Nerve growth factor as a paradigm of neurotrophins related to Alzheimer’s disease. Dev Neurobiol 2010, 70(5): 372–383.
DOI Google Scholar
[76]
Lee IS, Jung K, Kim IS, Lee H, Kim M, Yun S, Hwang K, Shin JE, Park KI. Human neural stem cells alleviate Alzheimer-like pathology in a mouse model. Mol Neurodegener 2015, 10: 38.
DOI Google Scholar
[77]
Lilja AM, Malmsten L, Rojdner J, Voytenko L, Verkhratsky A, Ogren SO, Nordberg A, Marutle A. Neural stem cell transplant-induced effect on neurogenesis and cognition in Alzheimer Tg2576 mice is inhibited by concomitant treatment with amyloid-lowering or cholinergic alpha7 nicotinic receptor drugs. Neural Plast 2015, 2015: 370432.
DOI Google Scholar
[78]
Kim JA, Ha S, Shin KY, Kim S, Lee KJ, Chong YH, Chang KA, Suh YH. Neural stem cell transplantation at critical period improves learning and memory through restoring synaptic impairment in Alzheimer’s disease mouse model. Cell Death Dis 2015, 6: e1789.
DOI Google Scholar
[79]
Tarczyluk MA, Nagel DA, Rhein Parri H, Tse EH, Brown JE, Coleman MD, Hill EJ. Amyloid beta 1-42 induces hypometabolism in human stem cell-derived neuron and astrocyte networks. J Cereb Blood Flow Metab 2015, 35(8): 1348–1357.
DOI Google Scholar
[80]
Burke J, Kolhe R, Hunter M, Isales C, Hamrick M, Fulzele S. Stem cell-derived exosomes: A potential alternative therapeutic agent in orthopaedics. Stem Cells Int 2016, 2016:5802529.
DOI Google Scholar
[81]
Zhang B, Yeo RW, Tan KH, Lim SK. Focus on extracellular vesicles: Therapeutic potential of stem cell-derived extracellular vesicles. Int J Mol Sci 2016, 17(2): 174.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 08 January 2016
Revised: 29 February 2016
Accepted: 29 February 2016
Published: 01 March 2016
Issue date: March 2016

Copyright

© The authors 2016.

Rights and permissions

This article is published with open access at www.TNCjournal.com

Return